RT Journal Article
SR Electronic
T1 Microbial context predicts SARS-CoV-2 prevalence in patients and the hospital built environment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.19.20234229
DO 10.1101/2020.11.19.20234229
A1 Marotz, Clarisse
A1 Belda-Ferre, Pedro
A1 Ali, Farhana
A1 Das, Promi
A1 Huang, Shi
A1 Cantrell, Kalen
A1 Jiang, Lingjing
A1 Martino, Cameron
A1 Diner, Rachel E.
A1 Rahman, Gibraan
A1 McDonald, Daniel
A1 Armstrong, George
A1 Kodera, Sho
A1 Donato, Sonya
A1 Ecklu-Mensah, Gertrude
A1 Gottel, Neil
A1 Salas Garcia, Mariana C.
A1 Chiang, Leslie Y.
A1 Salido, Rodolfo A.
A1 Shaffer, Justin P.
A1 Bryant, MacKenzie
A1 Sanders, Karenina
A1 Humphrey, Greg
A1 Ackermann, Gail
A1 Haiminen, Niina
A1 Beck, Kristen L.
A1 Kim, Ho-Cheol
A1 Carrieri, Anna Paola
A1 Parida, Laxmi
A1 Vázquez-Baeza, Yoshiki
A1 Torriani, Francesca J.
A1 Knight, Rob
A1 Gilbert, Jack A.
A1 Sweeney, Daniel A.
A1 Allard, Sarah M.
YR 2020
UL http://medrxiv.org/content/early/2020/11/22/2020.11.19.20234229.abstract
AB Synergistic effects of bacteria on viral stability and transmission are widely documented but remain unclear in the context of SARS-CoV-2. We collected 972 samples from hospitalized patients with coronavirus disease 2019 (COVID-19), their health care providers, and hospital surfaces before, during, and after admission. We screened for SARS-CoV-2 using RT-qPCR, characterized microbial communities using 16S rRNA gene amplicon sequencing, and contextualized the massive microbial diversity in this dataset through meta-analysis of over 20,000 samples. Sixteen percent of surfaces from COVID-19 patient rooms were positive, with the highest prevalence in floor samples next to patient beds (39%) and directly outside their rooms (29%). Although bed rail samples increasingly resembled the patient microbiome over time, SARS-CoV-2 was detected less there (11%). Despite viral surface contamination in almost all patient rooms, no health care workers contracted the disease, suggesting that personal protective equipment was effective in preventing transmissions. SARS-CoV-2 positive samples had higher bacterial phylogenetic diversity across human and surface samples, and higher biomass in floor samples. 16S microbial community profiles allowed for high SARS-CoV-2 classifier accuracy in not only nares, but also forehead, stool, and floor samples. Across distinct microbial profiles, a single amplicon sequence variant from the genus Rothia was highly predictive of SARS-CoV-2 across sample types and had higher prevalence in positive surface and human samples, even compared to samples from patients in another intensive care unit prior to the COVID-19 pandemic. These results suggest that bacterial communities may contribute to viral prevalence both in the host and hospital environment.One Sentence Summary Microbial classifier highlights specific taxa predictive of SARS-CoV-2 prevalence across diverse microbial niches in a COVID-19 hospital unit.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by IBM Research AI through the AI Horizons Network and the UC San Diego Center for Microbiome Innovation (to SH, KC, YVB, and RK). RED is supported by NIH/NIGMS IRACDA K12 (GM068524) and the National Science Foundation PRFB (P2011025). RK is supported by NIH Pioneer (1DP1AT010885) and NIH/NIDDK (1P30DK120515).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants were consented under UCSD Human Research Protections Program protocol 200613.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data is available through the European Bioinformatics Institute under accession ERP124721. https://www.ebi.ac.uk/ena/browser/view/PRJEB41002